glp-1 receptor agonists for type 2 diabetes individualized treatment of mellitus New Developments in Pharmacological Treatment
Description
Ding HR, Wang JL, Ren HZ, Shi XL
By setting prices at levels that are inaccessible to many, manufacturers of GLP-1 products effectively exclude large segments of the population who could benefit from these treatments
& Sharma, K
Accordingly, NAD availability may act as a rate-limiting metabolic currency whose adequacy is reflected by redox ratios and indicators of NAD turnover
Yang F, Zheng T, Gao Y, et al
Brazil Novo Tried to Stop the Clock and Couldnt Novo Nordisk went to Brazils Supreme Court to seek a patent extension
